Evidence map›Paper›PMID 35969113›Full record

ArticleAllergy2023

Long-term changes in milk component immunoglobulins reflect milk oral immunotherapy outcomes in Finnish children.

Tiina Kaisa Kauppila, Victoria Hinkkanen, Terhi Savinko, Piia Karisola, Anna Kaarina Kukkonen, Marita Paassilta, Anna S Pelkonen, Mika J Mäkelä

Open access · greenAbstract read
In one paragraph

Article in Allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Tiina Kaisa KauppilaUniversity of Helsinki, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0001-8254-8608
Victoria HinkkanenUniversity of Helsinki, Helsinki, Finland.ORCID 0000-0001-8281-6860
Terhi SavinkoSkin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0003-4483-7235
Piia KarisolaUniversity of Helsinki, Helsinki, Finland.ORCID 0000-0003-0635-2704
Anna Kaarina KukkonenNew Children's Hospital, Helsinki, Finland.ORCID 0000-0002-1178-5873
Marita PaassiltaAllergy Center, Tampere University Hospital, Tampere, Finland.ORCID 0000-0002-0854-4251
Anna S PelkonenSkin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-1482-8947
Mika J MäkeläUniversity of Helsinki, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-2933-3111
University of Helsinki · FIHelsinki University Hospital · FIHelsinki Children's Hospital · FITampere University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMilk oral immunotherapy (OIT) may increase the amount of milk protein that can be ingested without triggering an allergic reaction. It is important to understand why some patients benefit from the treatment while others do not.

objectiveThe aim was to define the differences in the milk allergen component-specific (casein, α-lactalbumin, ß-lactoglobulin) immunoglobulin (sIg [sIgE, sIgG4, and sIgA]) levels relative to the long-term outcomes of milk OIT.

methodsIn this long-term, open-label follow-up study, 286 children started milk OIT between 2005 and 2015. Follow-up data were collected at two points: the post-buildup phase and long term (range 1-11 years, median 6 years). Comparisons of sIg levels were made among three outcome groups of self-reported long-term milk consumption (high-milk dose, low-milk dose, and avoidance).

resultsA total of 168 (59%) of the 286 patients on OIT participated. Most patients (57%) were in the high-dose group; here, 80% of these patients had a baseline casein sIgE value less than 28 kUA/L, they had the lowest casein sIgE levels at all time (p < .001), their casein sIgG4/IgE levels increased, and long-term casein sIgA was highest compared with the low-dose and avoidance groups (p = .02). Low-milk dose group had the highest casein sIgG4/IgE levels in long term (p = .002).

conclusionThe baseline Ig profiles and responses to milk OIT differed depending on long-term milk consumption. Lower casein sIgE levels were associated with better outcome. Milk casein sIgA differed in the long term among high-milk consumers.

Indexed as

CaseinsMilk HypersensitivityAdministration, OralAllergensChildDesensitization, ImmunologicFinlandFollow-Up StudiesHumansImmunoglobulin A, SecretoryImmunoglobulin EImmunotherapyAllergensCaseinsImmunoglobulin A, SecretoryImmunoglobulin Ecow's milk allergyimmunoglobulinslong-term follow-upmilk componentsoral immunotherapy

Identifiers

PMID35969113
PMCPMC10087274
OpenAlexW4291901366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.